Aaron Gal
Stock Analyst at Bernstein
(1.57)
# 2,308
Out of 4,433 analysts
11
Total ratings
63.64%
Success rate
9.76%
Average return
Main Sectors:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,125 | $967.98 | +16.22% | 3 | Mar 11, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $130 → $155 | $164.35 | -5.69% | 1 | Jan 3, 2022 | |
| BIIB Biogen | Upgrades: Outperform | n/a | $230.04 | - | 2 | Jun 11, 2021 | |
| GILD Gilead Sciences | Upgrades: Outperform | n/a | $67.86 | - | 2 | Apr 1, 2021 | |
| VTRS Viatris | Initiates: Market Perform | n/a | $11.02 | - | 1 | Dec 14, 2020 | |
| AMGN Amgen | Downgrades: Market Perform | n/a | $314.72 | - | 1 | Oct 9, 2020 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $16.30 | - | 1 | Aug 4, 2017 |
Regeneron Pharmaceuticals
Mar 11, 2024
Initiates: Outperform
Price Target: $1,125
Current: $967.98
Upside: +16.22%
AbbVie
Jan 3, 2022
Maintains: Outperform
Price Target: $130 → $155
Current: $164.35
Upside: -5.69%
Biogen
Jun 11, 2021
Upgrades: Outperform
Price Target: n/a
Current: $230.04
Upside: -
Gilead Sciences
Apr 1, 2021
Upgrades: Outperform
Price Target: n/a
Current: $67.86
Upside: -
Viatris
Dec 14, 2020
Initiates: Market Perform
Price Target: n/a
Current: $11.02
Upside: -
Amgen
Oct 9, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $314.72
Upside: -
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $16.30
Upside: -